Kala Pharmaceuticals, Inc.
General ticker "KALA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $35.7M (TTM average)
Kala Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 3.2%.
Estimated limits based on current volatility of 23.7%: low 1.00$, high 1.55$
Factors to consider:
- Total employees count: 43 (+26.5%) as of 2023
- Top business risk factors: High R&D costs, Labor/talent shortage/retention, Regulatory and compliance, Operational and conduct risks, Market competition
- Current price 72.9% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.55$, 11.01$]
- 2025-12-31 to 2026-12-31 estimated range: [2.06$, 6.78$]
Financial Metrics affecting the KALA estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -83.09 <= 0.33
- Positive: 18.93 < Shareholder equity ratio, % of 22.23 <= 41.86
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0.84
- Positive: Investing cash flow per share per price, % of -0.59 > -0.66
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term KALA quotes
Long-term KALA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.89MM | $0.00MM | $0.00MM |
| Operating Expenses | $85.25MM | $39.15MM | $40.98MM |
| Operating Income | $-81.36MM | $-39.15MM | $-40.98MM |
| Non-Operating Income | $36.53MM | $-3.05MM | $2.47MM |
| Interest Expense | $7.27MM | $5.81MM | $5.78MM |
| R&D Expense | $17.65MM | $18.59MM | $22.09MM |
| Income(Loss) | $-44.82MM | $-42.20MM | $-38.51MM |
| Profit(Loss)* | $-44.82MM | $-42.20MM | $-38.51MM |
| Stockholders Equity | $18.97MM | $7.50MM | $12.33MM |
| Assets | $86.82MM | $55.95MM | $55.48MM |
| Operating Cash Flow | $-78.91MM | $-27.93MM | $-29.38MM |
| Capital expenditure | $0.31MM | $0.61MM | $0.21MM |
| Investing Cash Flow | $62.72MM | $-0.43MM | $-0.21MM |
| Financing Cash Flow | $-7.94MM | $8.51MM | $29.88MM |
| Earnings Per Share** | $-29.48 | $-17.35 | $-6.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.